Drugs / GC4702
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03096756 | Jul → Dec 2016 | — | Galera Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC4702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03096756 ↗ |
| Route | Oral | “single oral dose of escalating doses of the encapsulated dry powder GC4702 formulation” NCT03096756 ↗ |